IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.
about
Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissuesThe immunoregulatory role of type I and type II NKT cells in cancer and other diseasesIL15 and T-cell Stemness in T-cell-Based Cancer ImmunotherapyDifferential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.GD2-targeted immunotherapy and radioimmunotherapyNeuroblastoma: developmental biology, cancer genomics and immunotherapy.Human cancer growth and therapy in immunodeficient mouse models.Neuroblastoma: molecular pathogenesis and therapy.Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.Invariant Natural Killer T Cell Deficiency and Functional Impairment in Sleep Apnea: Links to Cancer ComorbidityIL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer.Glycolysis determines dichotomous regulation of T cell subsets in hypoxiaTargeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.Humanized Mouse Models of Clinical Disease.The tumor microenvironment: a pitch for multiple players.Immunosuppressive microenvironment in neuroblastoma.Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression.Immunotherapeutic strategies targeting natural killer T cell responses in cancer.MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene.Tumor-associated macrophages: implications in cancer immunotherapy.The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.Unleashing the immune response against childhood solid cancers.Modeling Natural Killer Cell Targeted Immunotherapies.Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges.Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32.Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis.Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia.Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation.Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.Tumor-infiltrating lymphocytes (TILs) from patients with glioma.Obesity exacerbates colitis-associated cancer via IL-6-regulated macrophage polarisation and CCL-20/CCR-6-mediated lymphocyte recruitment.Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.
P2860
Q27003907-E4483516-06FD-4FE2-8F74-5D022C33D49BQ27027556-3208E988-3911-4AA3-8724-5EC5509716F1Q28088543-144DF338-7D44-4EA4-9503-81107F13B9E3Q30412235-D5284BF6-6F58-4216-95FB-256F16E4313DQ33711371-1E8D8F06-E855-41C2-A635-77593ABE073AQ34431441-261C3F20-3A43-47F7-9A1F-00184B13B6C8Q34625339-2D14911E-275D-49BD-88C1-EA3407C323D5Q35283020-51EA4E4A-DC53-4121-B190-23733DCE9BC4Q35545282-D00A85EC-8FAE-499E-B0F3-8DF9F1390211Q35564199-D7F8857A-97F3-4E6F-921F-97CC19866217Q35664913-4F9FF180-2F91-4E19-B672-DA2DF5B97BC0Q36076707-2362A3A6-FC52-4BF5-9522-3E957488B277Q36335722-87893E99-C765-4CA6-96EB-02A27E94E9F6Q37042215-5A7823A4-5413-4C8B-9AB2-E9D45A0659BAQ37592957-BF7E5981-AC7C-40D8-B10F-A5FBD1884F68Q37614202-FAC93CCE-2A0B-4745-8F27-5BC9CDC8AF77Q38101567-E92ADD26-05D9-45A5-A709-5BE4CDFDC442Q38117379-E69B46A8-BB4F-478B-B866-E76C454D7DB9Q38734173-C6A60653-F161-4194-8A39-72FECEB65946Q38890717-1B080237-7CA2-4D68-9010-5267CAF2D3A2Q39129449-A5F26E4F-3918-44CA-9C4D-FB614FEE6924Q39148281-BA5A6C25-2218-4A87-8318-32D69A6E00E3Q39148534-B034F88D-723A-461B-A8A2-5531BCF17BF3Q39224315-00F996CE-C8C0-4CD5-A34F-C686D356C17BQ39239278-09D6A9E6-30F3-4A46-9CE4-93F82B2821A0Q39283173-64F365C7-94A9-4893-BB7C-6940E82FA273Q40858793-92A4A5D7-5F20-40D7-8911-344564658F39Q41548165-276FF859-1121-4D53-8DD2-16028815D55BQ41636566-ADC391AC-CAC5-4349-82D3-21DBAE9B9A99Q41686071-5B52CD64-25E8-4153-A04F-A1D6B1707615Q42650181-CF923948-FE56-4375-9AD7-48E6C68980A4Q43555934-AFD5DF9B-30EE-4054-860E-D72732B3056FQ45868285-A6A8C15B-632A-49DE-9F8E-F071FD5806F3Q45871070-C979637C-0688-45D8-88E7-59E1373C7E57Q47160952-D9D02B09-149C-485C-BDC0-D87361681987Q50075685-31404A47-6138-477C-860D-5D65F0B7EFBDQ50590539-D14EB837-1D45-4BFC-96E5-F2A80E01BEA7Q52562781-F1A37F64-8A88-45C4-B8C0-0CEC190D485EQ52645931-B79469BB-47B8-406E-A0F8-2E2A63CE2310Q52717590-8C9013D1-2824-419C-8A8F-AA5BCFE1293A
P2860
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
IL-15 protects NKT cells from ...... ances antimetastatic activity.
@ast
IL-15 protects NKT cells from ...... ances antimetastatic activity.
@en
type
label
IL-15 protects NKT cells from ...... ances antimetastatic activity.
@ast
IL-15 protects NKT cells from ...... ances antimetastatic activity.
@en
prefLabel
IL-15 protects NKT cells from ...... ances antimetastatic activity.
@ast
IL-15 protects NKT cells from ...... ances antimetastatic activity.
@en
P2093
P2860
P356
P1476
IL-15 protects NKT cells from ...... hances antimetastatic activity
@en
P2093
Amy N Courtney
Andras Heczey
Daofeng Liu
Ekaterina Marinova
Eugene Kim
Gianpietro Dotti
Leonid S Metelitsa
Linjie Guo
Liping Song
P2860
P304
P356
10.1172/JCI59535
P407
P577
2012-05-08T00:00:00Z